Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3541105 · 1 trial · 2 indications
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY3541105 (Part A) | EXPERIMENTAL | Single ascending doses of LY3541105 administered subcutaneously (SC). |
| LY3541105 (Part B) | EXPERIMENTAL | Multiple ascending doses of LY3541105 administered SC. |
| LY3541105 (Part C) | EXPERIMENTAL | Escalating doses of LY3541105 administered SC. |
| Placebo (Part A) | PLACEBO_COMPARATOR | Placebo administered SC. |
| Placebo (Part B) | PLACEBO_COMPARATOR | Placebo administered SC. |
| Placebo (Part C) | PLACEBO_COMPARATOR | Placebo administered SC. |
| Name | Type | Description |
|---|---|---|
| LY3541105 | DRUG | Administered SC. |
| Placebo | DRUG | Administered SC. |
Inclusion Criteria: * Participants who are overtly healthy as determined by medical evaluation * Male participants who agree to refrain from sperm donation and to use contraceptive methods and female participants not of childbearing potential * Have a body mass index (BMI) in the range of greater t...
LY3541105 is an investigational small molecule being developed for overweight. It is a metabolic therapeutic being studied in healthy and overweight participants. The drug is currently in Phase 1 clinical development and is not approved by the FDA.
LY3541105 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the NYSE under the ticker LLY. The company is conducting clinical trials to evaluate the drug's safety and tolerability in overweight participants.
LY3541105 is in Phase 1 clinical development. A Phase 1 study of the drug has been completed. The drug is investigational and has not been approved by the FDA.
LY3541105 has one completed clinical trial, NCT05380323, titled "A Study of LY3541105 in Healthy and Overweight Participants." This Phase 1 study enrolled 206 participants in the United States and was randomized, double-blind, and placebo-controlled.
LY3541105 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. A Phase 1 study has been completed, but the drug has not yet received regulatory approval.